Ubiquilin 2 enhances osteosarcoma progression through resistance to hypoxic stress.

• 資料種別: 博士論文
• タイトル: Ubiquilin 2 enhances osteosarcoma progression through resistance to hypoxic stress.
• 著者・編者: Tsukamoto, Shinji; Shimada, Keiji; Honoki, Kanya; Kido, Akira; Akahane, Manabu; Tanaka, Yasuhito; Konishi, Noboru
• 著者標目: Tsukamoto, Shinji; Shimada, Keiji; Honoki, Kanya; Kido, Akira; Akahane, Manabu; Tanaka, Yasuhito; Konishi, Noboru
• 出版事項: Spandidos
• 出版年月日等: 2015-04
• 出版年（W3CDTF）: 2015-04
• 並列タイトル等: ユビキリン２は低酸素ストレスに耐性を示すことで骨肉腫の増殖を促進させる
• タイトル（掲載誌）: Oncology reports
• 巻号年月日等（掲載誌）: 33 4
• 掲載巻: 33
• 掲載号: 4
• 掲載ページ: 1799-1806
• ISSN（掲載誌）: ISSN : 1021-335X
• 授与機関名: 奈良県立医科大学
• 授与年月日: 2015-05-28
• 報告番号: 甲第637号
• 学位: 博士（医学）
• 本文の言語コード: eng
• 件名標目: ubiquilin 2; osteosarcoma; hypoxia; HIF-1α; apoptosis
• 対象利用者: 一般
• 一般注記: type:Thesis; Ubiquilin 2 (UBQLN2), a member of the ubiquitin-like protein family (ubiquilins), maintains protein homeostasis. Although UBQLN2 has been implicated in the pathogenesis of neurodegenerative diseases, it is also associated with mali­gnant tumors. Therefore, we examined whether UBQLN2 plays a role in human osteosarcoma. The human osteosarcoma cell line MG63 was transfected with UBQLN2 siRNA and cultured under hypoxic conditions. The rat osteosarcoma cell line COS1NR was inoculated into Fischer 344 rats, followed by injection of UBQLN2 siRNA with atelocollagen. An immunohistochemical analysis of UBQLN2 was performed using 34 cases of human high-grade osteosarcomas, and metastasis-free survival was estimated by the Kaplan-Meier method. Silencing of UBQLN2 by siRNA transfection under hypoxia led to activation of JNK and p38, resulting in induction of apoptosis in the osteosarcoma cell line MG63. Injection of UBQLN2 siRNA suppressed tumor growth in the rat osteosarcoma model, followed by apoptosis induction. The immunohistochemical examination revealed that high UBQLN2 expression was significantly associated with the unfavorable metastasis-free survival of osteosarcoma patients. UBQLN2 plays an important role in resistance to hypoxic stress and enhances tumor progression in osteosarcoma. UBQLN2 may be a new molecular target for chemotherapeutics and a useful clinicopathological marker in human osteosarcoma.; 博士（医学）・甲第637号・平成27年5月28日; Copyright © Spandidos Publications 2015; 本文のリンク：http://dx.doi.org/10.3892/or.2015.3788; identifier:Oncology reports Vol.33 No.4 p.1799-1806(2015.04); identifier:1021335X; identifier:http://ginmu.naramed-u.ac.jp/dspace/handle/10564/3070; identifier:Oncology reports, 33(4): 1799-1806
• オンライン閲覧公開範囲: インターネット公開
• 関連情報（DOI）: 10.3892/or.2015.3788
• 連携機関・データベース: 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• 提供元機関・データベース: 奈良県立医科大学 : 奈良県立医科大学機関リポジトリ GINMU

目次

http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/3070/1/01_%e7%94%b2637%e6%9c%ac%e6%96%87%e3%81%ae%e8%a6%81%e6%97%a8.pdf fulltext

http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/3070/2/02_%e7%94%b2637%e5%af%a9%e6%9f%bb%e8%a6%81%e6%97%a8.pdf fulltext

http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/3070/6/03_%e7%94%b2637%e6%9c%ac%e6%96%87.pdf fulltext